Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.30 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18525000 | 0.98 | ALDH1A1 (0.33) | ATMALDH1A1HRH3LMNAHTT | |
| SCHEMBL21119148 | 0.86 | LTA4H (0.33) | ALDH1A1HRH3TDP1 | |
| SCHEMBL14098302 | 0.85 | LTA4H (0.35) | ALDH1A1HRH3SIGMAR1TDP1 | |
| SCHEMBL19507607 | 0.84 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL20901286 | 0.83 | LTA4H (0.38) | ALDH1A1HRH3TDP1 | |
| SCHEMBL20333626 | 0.82 | SIGMAR1 (0.36) | ALDH1A1LMNAHTTSIGMAR1 | |
| SCHEMBL19230337 | 0.82 | HTT (0.36) | ALDH1A1HTT | |
| SCHEMBL11501574 | 0.82 | LMNA (0.36) | ATMALDH1A1HRH3LMNASIGMAR1 | |
| SCHEMBL18824000 | 0.80 | — | — | |
| SCHEMBL19633992 | 0.80 | ALDH1A1 (0.38) | ALDH1A1HRH3LMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ALLCRON PHARMA INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ALLCRON PHARMA INC. | 2021-02-11 | — | — | US | disclosed |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | ATM 4033/4885ALDH1A1 2393/4885HRH3 4454/4885 |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | ATM 1192/4885ALDH1A1 2886/4885HRH3 1724/4885 |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | ATM 2097/4885ALDH1A1 691/4885HRH3 30/4885 |
| US-20210040104-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | ATM 647/4885ALDH1A1 3210/4885HRH3 3520/4885 |
| US-20230399337-A1 | NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE | ABL1, MCL1, ABL2 | ATM 647/4885ALDH1A1 3210/4885HRH3 3520/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | ATM 2097/4885ALDH1A1 691/4885HRH3 30/4885 |
| US-11697654-B2 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | ABL1, MCL1, ABL2 | ATM 544/4885ALDH1A1 2686/4885HRH3 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.